Loading...
•
Dec 31, 2023
Aytu BioScience Q2 2024 Earnings Report
Aytu BioScience reported record ADHD revenue and operating income.
Key Takeaways
Aytu BioScience, Inc. reported a net revenue of $22.9 million for Q2 2024, with operating income reaching $2.4 million, marking the company's first quarter of positive operating income. The ADHD Portfolio revenue increased by 49% year-over-year to $16.6 million. Net loss for the quarter was $0.2 million, or $0.04 per share.
Consolidated net revenue was $22.9 million.
ADHD Portfolio net revenue increased 49% to $16.6 million.
Consolidated operating income was $2.4 million.
Net loss was $0.2 million, or $0.04 per share.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
ADHD Portfolio Revenue
CapyFin.comPediatric Portfolio Revenue
CapyFin.comOther Revenue
CapyFin.com Forward Guidance
Aytu BioPharma is focused on maximizing the potential of its Rx brands and continuing to drive improvement in long-term stockholder value. The company expects to see further operational improvements throughout calendar year 2024.
Revenue & Expenses
Visualization of income flow from segment revenue to net income